Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis.
10.3760/cma.j.cn501113-20220622-00342
- VernacularTitle:肝硬化合并糖尿病患者血糖管理专家共识
- Collective Name:Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association
- Publication Type:Journal Article
- MeSH:
Consensus;
Diabetes Mellitus/therapy*;
Diabetes Mellitus, Type 2/complications*;
Humans;
Hypoglycemic Agents/therapeutic use*;
Liver Cirrhosis/therapy*;
Non-alcoholic Fatty Liver Disease/complications*
- From:
Chinese Journal of Hepatology
2022;30(8):846-858
- CountryChina
- Language:Chinese
-
Abstract:
In view of the high prevalence of diabetes mellitus in patients with liver cirrhosis and the increasing trend of non-alcoholic fatty liver disease-associated cirrhosis, the diagnosis and treatment of diabetes mellitus in patients with liver cirrhosis are becoming widespread concerns. Therefore, the Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association, organized multidisciplinary experts from gastroenterology, infective disease, endocrinology, etc, to draw up expert consensus on the management of diabetes mellitus in patients with liver cirrhosis, with focusing on the classification and management of hyperglycemia in cirrhotic patients. The consensus summarizes the prevalence, pathogenesis, clinical setting and prognosis of the concomitant diabetes mellitus in patients with liver cirrhosis, and definitely puts forward a proposal regarding "hepatogenous diabetes" as one of the four subtypes of diabetes mellitus in cirrhotic patients, and further recommends the basic principles for diagnosing and monitoring diabetes mellitus and the selection of antidiabetic drugs based on liver functions in patients with liver cirrhosis.
